WO2018071701A1 - Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a - Google Patents

Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a Download PDF

Info

Publication number
WO2018071701A1
WO2018071701A1 PCT/US2017/056386 US2017056386W WO2018071701A1 WO 2018071701 A1 WO2018071701 A1 WO 2018071701A1 US 2017056386 W US2017056386 W US 2017056386W WO 2018071701 A1 WO2018071701 A1 WO 2018071701A1
Authority
WO
WIPO (PCT)
Prior art keywords
masp
antibody
seq
fibrosis
inhibitory
Prior art date
Application number
PCT/US2017/056386
Other languages
English (en)
Inventor
Nigel John BRUNSKILL
Gregory A. Demopulos
Tom DUDLER
Hans-Wilhelm Schwaeble
Original Assignee
University Of Leicester
Omeros Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Priority to SG11201902941UA priority Critical patent/SG11201902941UA/en
Priority to EP17861108.3A priority patent/EP3525798A4/fr
Priority to AU2017342428A priority patent/AU2017342428B2/en
Priority to NZ753260A priority patent/NZ753260B2/en
Priority to CA3039927A priority patent/CA3039927C/fr
Priority to UAA201904866A priority patent/UA126908C2/uk
Priority to JP2019520140A priority patent/JP6893554B2/ja
Priority to MX2019004074A priority patent/MX2019004074A/es
Application filed by University Of Leicester, Omeros Corporation filed Critical University Of Leicester
Priority to BR112019007426A priority patent/BR112019007426A2/pt
Priority to KR1020197012865A priority patent/KR102348939B1/ko
Priority to EA201990903A priority patent/EA201990903A1/ru
Priority to CN202310450575.2A priority patent/CN116726163A/zh
Priority to CN201780060710.5A priority patent/CN110177557A/zh
Publication of WO2018071701A1 publication Critical patent/WO2018071701A1/fr
Priority to PH12019500711A priority patent/PH12019500711A1/en
Priority to IL265981A priority patent/IL265981A/en
Priority to ZA2019/02933A priority patent/ZA201902933B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Husbandry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)

Abstract

Dans un aspect, l'invention concerne des méthodes de réduction de la protéinurie chez un sujet humain souffrant ou présentant un risque de développer une néphropathie aux immunoglobulines A (IgAN). Les méthodes comprennent l'étape d'administration, à un sujet qui en a besoin, d'une quantité d'un agent inhibiteur de MASP-2 efficace pour inhiber l'activation du complément dépendant de MASP-2.
PCT/US2017/056386 2016-10-13 2017-10-12 Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a WO2018071701A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CN202310450575.2A CN116726163A (zh) 2016-10-13 2017-10-12 用于减少患有免疫球蛋白a肾病的人受试者中的蛋白尿的方法
CN201780060710.5A CN110177557A (zh) 2016-10-13 2017-10-12 用于减少患有免疫球蛋白a肾病的人受试者中的蛋白尿的方法
BR112019007426A BR112019007426A2 (pt) 2016-10-13 2017-10-12 método para reduzir a proteinúria em um sujeito humano que sofre de igan.
AU2017342428A AU2017342428B2 (en) 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a Nephropathy
NZ753260A NZ753260B2 (en) 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
CA3039927A CA3039927C (fr) 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2
UAA201904866A UA126908C2 (uk) 2016-10-13 2017-10-12 Спосіб зменшення протеїнурії у людини, що страждає від імуноглобулін a-нефропатії
JP2019520140A JP6893554B2 (ja) 2016-10-13 2017-10-12 免疫グロブリンａ腎症に罹患したヒト対象におけるタンパク尿を低減するための方法
MX2019004074A MX2019004074A (es) 2016-10-13 2017-10-12 Metodos para la reduccion de proteinuria en un sujeto humano que padece nefropatia por inmunoglobulina a.
SG11201902941UA SG11201902941UA (en) 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
EP17861108.3A EP3525798A4 (fr) 2016-10-13 2017-10-12 Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a
KR1020197012865A KR102348939B1 (ko) 2016-10-13 2017-10-12 면역글로불린 a 신증을 앓고 있는 인간 대상체에서 단백뇨를 감소시키는 방법
EA201990903A EA201990903A1 (ru) 2017-06-30 2017-10-12 Способ уменьшения протеинурии у человека, страдающего от иммуноглобулин а нефропатии
PH12019500711A PH12019500711A1 (en) 2016-10-13 2019-04-01 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
IL265981A IL265981A (en) 2016-10-13 2019-04-11 Methods for reducing proteinuria in a human patient suffering from immunoglobulin a nephropathy
ZA2019/02933A ZA201902933B (en) 2016-10-13 2019-05-10 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US62/407,979 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/399,524 2017-01-05
US15/470,647 2017-03-27
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30
US62/527,926 2017-06-30

Publications (1)

Publication Number Publication Date
WO2018071701A1 true WO2018071701A1 (fr) 2018-04-19

Family

ID=61906454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/056386 WO2018071701A1 (fr) 2016-10-13 2017-10-12 Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a

Country Status (18)

Country Link
EP (1) EP3525798A4 (fr)
JP (1) JP6893554B2 (fr)
KR (1) KR102348939B1 (fr)
CN (2) CN116726163A (fr)
AU (1) AU2017342428B2 (fr)
BR (1) BR112019007426A2 (fr)
CA (2) CA3039927C (fr)
CL (2) CL2019000909A1 (fr)
GE (1) GEP20247587B (fr)
IL (1) IL265981A (fr)
JO (1) JOP20190068A1 (fr)
MA (1) MA46541A (fr)
MX (1) MX2019004074A (fr)
PH (1) PH12019500711A1 (fr)
SG (1) SG11201902941UA (fr)
UA (1) UA126908C2 (fr)
WO (1) WO2018071701A1 (fr)
ZA (1) ZA201902933B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN117016486A (zh) * 2023-07-20 2023-11-10 澎立生物医药技术(上海)股份有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110311549A1 (en) * 2004-06-10 2011-12-22 Leicester, University Of Methods for treating conditions associated with masp-2 dependent complement activation
US20140127224A1 (en) * 2011-01-21 2014-05-08 Fibrogen, Inc. Therapeutic Method
US20150166675A1 (en) * 2013-10-17 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US9096676B2 (en) * 2003-05-12 2015-08-04 Helion Biotech Aps Antibodies to MASP-2
US20170189525A1 (en) * 2016-01-05 2017-07-06 University Of Leicester Methods for Inhibiting Fibrosis in a Subject in Need Thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7626730B2 (en) * 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
JP5911804B2 (ja) * 2009-10-16 2016-04-27 オメロス コーポレーション Ｍａｓｐ−２依存性の補体活性化を阻害することによって播種性血管内凝固を処置するための方法
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR20220044616A (ko) * 2011-04-08 2022-04-08 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
EP2704743B1 (fr) * 2011-05-04 2020-03-11 Omeros Corporation Compositions pour inhibition d'activation du complément dépendant de masp-2
US20150017162A1 (en) * 2013-03-15 2015-01-15 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096676B2 (en) * 2003-05-12 2015-08-04 Helion Biotech Aps Antibodies to MASP-2
US20110311549A1 (en) * 2004-06-10 2011-12-22 Leicester, University Of Methods for treating conditions associated with masp-2 dependent complement activation
US20140127224A1 (en) * 2011-01-21 2014-05-08 Fibrogen, Inc. Therapeutic Method
US20150166675A1 (en) * 2013-10-17 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US20170189525A1 (en) * 2016-01-05 2017-07-06 University Of Leicester Methods for Inhibiting Fibrosis in a Subject in Need Thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RICKLIN ET AL.: "Complement in Immune and Inflammatory Disorders: Therapeutic Interventions", THE JOURNAL OF IMMUNOLOGY, vol. 190, 15 April 2013 (2013-04-15), pages 3839 - 3847, XP055246658 *
ROOS ET AL.: "Glomerular Activation of the Lectin Pathway of Complement in IgA Nephropathy is Associated with More Severe Renal Disease", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 17, 1 June 2006 (2006-06-01), pages 1724 - 1734, XP002674417 *
TANG ET AL.: "Mycophenolate Mofetil Alleviates Persistent Proteinuria in IgA Nephropathy", KIDNEY INTERNATIONAL, vol. 68, 31 August 2005 (2005-08-31), pages 802 - 812, XP055475049 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN117016486A (zh) * 2023-07-20 2023-11-10 澎立生物医药技术(上海)股份有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法

Also Published As

Publication number Publication date
JOP20190068A1 (ar) 2019-04-01
UA126908C2 (uk) 2023-02-22
MX2019004074A (es) 2019-06-10
CA3039927C (fr) 2023-10-10
CA3210384A1 (fr) 2018-04-19
JP6893554B2 (ja) 2021-06-23
CN116726163A (zh) 2023-09-12
AU2017342428A1 (en) 2019-05-23
PH12019500711A1 (en) 2019-11-18
KR20190063475A (ko) 2019-06-07
AU2017342428B2 (en) 2021-02-04
CA3039927A1 (fr) 2018-04-19
JP2019534271A (ja) 2019-11-28
KR102348939B1 (ko) 2022-01-12
BR112019007426A2 (pt) 2019-07-02
CL2019000909A1 (es) 2019-06-14
CL2019003485A1 (es) 2020-04-13
NZ753260A (en) 2021-11-26
GEP20247587B (en) 2024-01-25
CN110177557A (zh) 2019-08-27
EP3525798A4 (fr) 2020-07-08
ZA201902933B (en) 2023-05-31
EP3525798A1 (fr) 2019-08-21
IL265981A (en) 2019-06-30
MA46541A (fr) 2019-08-21
SG11201902941UA (en) 2019-05-30

Similar Documents

Publication Publication Date Title
US20210077621A1 (en) Methods for inhibiting fibrosis in a subject in need thereof
US20210079116A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
US20210355236A1 (en) Methods for inhibiting fibrosis in a subject in need thereof
JP2023516727A (ja) コロナウイルス誘発性急性呼吸窮迫症候群の処置および／または予防のためにｍａｓｐ－２を阻害する方法
AU2017342428B2 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a Nephropathy
TWI834025B (zh) 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
OA18820A (en) Methods for inhibiting fibrosis in a subject in need thereof.
EA043102B1 (ru) Способ уменьшения протеинурии у человека, страдающего от иммуноглобулин а нефропатии
OA19229A (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17861108

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3039927

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019520140

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019007426

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197012865

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 15070

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 2017861108

Country of ref document: EP

Effective date: 20190513

ENP Entry into the national phase

Ref document number: 2017342428

Country of ref document: AU

Date of ref document: 20171012

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112019007426

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190411

ENP Entry into the national phase

Ref document number: 16204

Country of ref document: GE